Categories

País suma 561 casos COVID-19 el miércoles, 609 el jueves y 570 hoy viernes: 215.178 casos COVID-19 totales

País suma 561 casos COVID-19 el miércoles, 609 el jueves y 570 hoy viernes: 215.178 casos COVID-19 totales

País suma 561 casos COVID-19 el miércoles, 609 el jueves y 570 hoy viernes: 215.178 casos COVID-19 totalesViernes 26 de marzo, 2021. El país registró 561 casos nuevos de COVID-19 el miércoles 24 de marzo, 609 el jueves 25 de marzo y 570

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2076-pais-suma-561-casos-covid-19-el-miercoles-609-el-jueves-y-570-hoy-viernes-215-178-casos-covid-19-totales

 
Categories

Namoo Enterprise LLC Issues Voluntary Nationwide Recall of PremierZen Black 5000 Due to the Presence of Undeclared Sildenafil and Tadalafil

Little Ferry, NJ, Namoo Enterprise LLC is voluntarily recalling all lots within expiry of PremierZen Black 5000 capsules to the consumer level. FDA analysis has found the product to contain undeclared sildenafil and tadalafil. Sildenafil and tadalafil, known as phosphodiesterase (PDE-5) inhibitors,

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/namoo-enterprise-llc-issues-voluntary-nationwide-recall-premierzen-black-5000-due-presence

 
Categories

Benzedrex (propylhexedrine): Drug Safety Communication – FDA Warns that Abuse and Misuse of the Nasal Decongestant Causes Serious Harm

Abuse and misuse of OTC nasal decongestant propylhexedrine can lead to serious harm such as heart and mental health problems. Some of these complications, which include fast or abnormal heart rhythm, high blood pressure, and paranoia, can lead to hospitalization, disability, or death.

http://www.fda.gov/safety/medical-product-safety-information/benzedrex-propylhexedrine-drug-safety-communication-fda-warns-abuse-and-misuse-nasal-decongestant

 
Categories

Zydus Pharmaceuticals (USA) Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection, 50 mg/mL Due to Crystallization

Pennington, NJ, Zydus Pharmaceuticals (USA) Inc. is voluntarily recalling four lots of Acyclovir Sodium Injection, 50 mg/mL, 10 mL and 20 mL vials, to the Hospital/User level after receiving several complaints of crystallization in vials. Administration of crystalized Acyclovir Sodium Injection, 50

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/zydus-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-acyclovir-sodium-injection-50-mgml